Home > Insider Trading > Filing (0001209191-18-002599)

Filing Details

Accession Number:: 0001209191-18-002599
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-01-05 20:14:26
Reporting Period:: 2018-01-03

Accepted Time:: 2018-01-05 20:14:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1567514	Intra-Cellular Therapies Inc.	ITCI	Pharmaceutical Preparations (2834)	364742850

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1585669	E. Kimberly Vanover	C/O Intra-Cellular Therapies, Inc. 430 East 29Th Street New York NY 10016	Svp, Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-01-03	2,648	$0.00	12,776	No	4	M	Direct
Common Stock	Acquisiton	2018-01-04	1,554	$0.00	14,330	No	4	M	Direct
Common Stock	Disposition	2018-01-05	1,185	$17.37	13,145	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2018-01-03	2,648	$0.00	2,648	$0.00
Common Stock	Restricted Stock Units	Disposition	2018-01-04	1,554	$0.00	1,554	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2018-01-03	65,164	$0.00	65,164	$15.47
Common Stock	Restricted Stock Units	Acquisiton	2018-01-03	48,480	$0.00	48,480	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,298		No	4	M	Direct
1,554		No	4	M	Direct
65,164	2028-01-03	No	4	A	Direct
48,480		No	4	A	Direct

Footnotes

Restricted stock units convert into common stock on a one-for-one basis.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2017. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.97 to $17.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On January 3, 2017, the reporting person was granted 7,946 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On January 4, 2016, the reporting person was granted 4,661 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On January 3, 2018, the reporting person was granted options to purchase 65,164 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.